Will Kyle Bass's Win Lead To More Hedge Fund Patent Challenges?

As the sting of hedge fund manager Martin Shkreli’s Turing Pharmaceuticals raising the price of an important drug from $13.50 per tablet to $750, comes a victory for hedge fund manager Kyle Bass, who is challenging pharmaceutical patents and says his actions will lower drug prices.

U.S. Patent and Trademarket Office rules with Kyle Bass

In a victory for Bass, a tribunal at the U.S. Patent and Trademark Office was reported on Friday to have denied a request by Celgene Corp to sanction Bass and his Coalition for Affordable Drugs by throwing out their challenges to its patents.

In an odd-twist on the Robin Hood concept, Bass had taken short positions in various drug companies...